arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Pacira BioSciences, Inc.

PCRX
$24.98 ▼ -0.60 (-2.35%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
55
Health
Fair
Neutral
auto_awesome

Analytical Summary

Pacira BioSciences, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.1B
Dividend Yield
Revenue Growth 3.6%
Op. Margin 2.6%
ROIC 0.8%
FCF / Share $3.07
Trailing P/E 156.1x
Price / Book 1.5x
FCF Yield 12.3%
Debt / Equity 0.54
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$726.41M
↑ +3.6%
Net Income Profit after all expenses
$7.03M
↑ +107.1%
Operating Margin Operating profit as % of sales
2.6%
↑ +125.2% 36th
FCF / Share Free cash flow per share
$3.07
↓ -20.7%
Long-Term Debt Long-term obligations
$372.19M
↓ -36.4%

Health Breakdown

Profitability
50
Returns
46
Financial Health
52
Cash Quality
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters